AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read

Anderson Dyaarl Lee Jr. sold $4K of SERA

Anderson Dyaarl Lee Jr. (Chief Commercial Officer) sold 1,800 shares of SERA PROGNOSTICS, INC. (SERA) at $2.00 on 2026-09-10.

Original reporting
SEC EDGAR · Anderson Dyaarl Lee Jr.
Published Sep 11, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

Minimal impact due to small transaction size relative to holdings.

02

Market read

Routine insider transaction with negligible market effect.

03

What to watch

insider still holds 76,198 shares, indicating confidence

Relevance 3/10Novelty 3/10Timing: transaction dated 2026-09-10

Background

SEC Form 4 filing reporting an insider sale of 1,800 shares at $2.00 each.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

sale size is trivial; unlikely to affect price

Key entities

  • Officer
    Anderson Dyaarl Lee Jr.

    Chief Commercial Officer of Sera Prognostics, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SERA insider trading history →

Related articles

AUG 19
$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

fool.com2 min
AUG 12
$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

prnewswire.com6 min
AUG 12
$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t

SEC EDGAR 8-K4 min